Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of intralesional L19IL2 + L19TNF in skin cancers
2021-006041-36Phase 2Active
- Sponsor
- Philogen
- Start
- Dec 2021
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of darleukin and onfekafusp alfa in cutaneous malignancy, sponsored by Philogen. Primary endpoint: Confirmed Best Overall Response Rate. Started Dec 2021; status: active.
02
Drugs
darleukinonfekafusp alfa
03
Conditions
cutaneous malignancy
Beyond the preview
Go deeper on 2021-006041-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006041-36.